Patents Examined by Yong Chu
  • Processes for the production of (+)- “Nal” morphinan compounds
    Patent number: 8067596
    Abstract: The invention generally provides processes and intermediate compounds useful for the production of (+) nal morphinan compounds. In particular, the process encompasses synthetic routes for the production of (+) nal morphinan compounds or derivatives of (+) nal morphinan compounds from (+)-morphinan substrates such as (+)-hydrocodone, (+)-norhydrocodone or derivatives of either compound.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: November 29, 2011
    Assignee: Mallinckrodt LLC
    Inventors: Peter X. Wang, Tao Jiang, Gary L. Cantrell, David W. Berberich, Bobby N. Trawick, Subo Liao
  • Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
    Patent number: 8063067
    Abstract: Compounds of the formula (I): in which R, R1, R2 and R3 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes for the preparation of these compounds.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: November 22, 2011
    Assignee: Merck Patent GmbH
    Inventors: Jean Jacques Zeiller, Hervè Dumas, Valérie Guyard-Dangremont, Isabelle Berard, Francis Contard, Daniel Guerrier, Gérard Ferrand, Yves Bonhomme
  • Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof
    Patent number: 8063234
    Abstract: The present application relates to novel 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindole derivatives, processes for the preparation thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases, and the use thereof for the manufacture of medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: November 22, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Peter Kolkhof, Astrid Brüns, Kai Thede, Karl-Heinz Schlemmer, Alexander Hillisch, Dieter Lang, Michael Gerisch, Andreas Goeller, Rolf Grosser, Carsten Schmeck, Elisabeth Woltering, Olaf Prien, Holger Paulsen, Armin Kern
  • Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
    Patent number: 8063078
    Abstract: Certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R1, R2, P, P?, n, p, q, r and s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: November 22, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Harshad Kantilal Rami, Mervyn Thompson
  • Crystalline modification of fipronil
    Patent number: 8063092
    Abstract: The present invention relates to a crystalline modification of fipronil, to a process for the preparation of the same, to pesticidal and parasiticidal mixtures and compositions comprising said crystalline modification and to their use for combating pests and parasites.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: November 22, 2011
    Assignee: BASF SE
    Inventors: Heidi Emilia Saxell, Peter Erk, Claude Taranta, Thomas Kröhl, Gerhard Cox, Gautam R. Desiraju, Rahul Banerjee, Prashant M. Bhatt
  • Compounds for the treatment of proliferative disorders
    Patent number: 8058297
    Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein Ra, Rb, and R2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: November 15, 2011
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Lijun Sun, Jun Jiang, Christopher Borella, Shoujun Chen, Keizo Koya
  • Compounds as cannabinoid receptor ligands
    Patent number: 8058293
    Abstract: Disclosed herein are compounds of formula (I) wherein R1, R2, R3, R25a, R26a, X, and n are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions are also described.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: November 15, 2011
    Assignee: Abbott Laboratories
    Inventors: Teodozyj Kolasa, Jennifer M. Frost, Meena V. Patel, Steven P. Latshaw, Arturo Perez Medrano, Xueqing Wang, Karin Rose Marie Tietje, Sridhar Peddi, William A. Carroll
  • Method for preparing conjugates using polymer maleimides
    Patent number: 8058385
    Abstract: Methods for preparing conjugates using polymeric reagents bearing a maleimide are provided. Also provided are compositions comprising the conjugates.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: November 15, 2011
    Assignee: Nektar Therapeutics
    Inventors: Antoni Kozlowski, John Handley, Anthony G. Schaefer, Brian Bray, Ryan Odom, Tony L. Sander
  • Method for preparing 1,3-disubstituted pyrrolidine compounds
    Patent number: 8058454
    Abstract: A process for preparing substituted pyrrolidine compounds, including (5)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide hydrobromide, commonly known in the art as darifenacin, comprising reacting a pyrrolidine compound with a benzofuran derivative in the presence of a phase-transfer catalyst.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: November 15, 2011
    Assignee: Medichem, S.A.
    Inventors: Núria Soldevilla Madrid, Ernesto Durán López, Jordi Puig Serrano
  • Arylphenyl-substituted cyclic keto-enols
    Patent number: 8058210
    Abstract: The present invention relates to novel arylphenyl-substituted cyclic ketoenols of the formula (I) in which X represents halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkylsulphinyl, alkylsulphonyl, halogenoalkyl, halogenoalkoxy, halogenoalkenyloxy, nitro, cyano or in each case optionally substituted phenyl, phenoxy, phenylthio, phenylalkoxy or phenylalkylthio, Y represents in each case optionally substituted cycloalkyl, aryl or hetaryl, Z represents hydrogen, halogen, alkyl, alkoxy, alkenyloxy, halogenoalkyl, halogenoalkoxy, halogenoalkenyloxy, nitro or cyano, CKE represents one of the groups in which A, B, D, G and Q1 to Q6 are each as defined in the description, to a plurality of processes for their preparation and to their use as pesticides and herbicides.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: November 15, 2011
    Assignee: Bayer Cropscience AG
    Inventors: Folker Lieb, Reiner Fischer, Alan Graff, Udo Schneider, Thomas Bretschneider, Christoph Erdelen, Wolfram Andersch, Mark-Wilhelm Drewes, Markus Dollinger, Ingo Wetcholowsky, Randy Allen Myers
  • Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
    Patent number: 8058313
    Abstract: ?,?-Unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides of Formula I: wherein R1, R2, M1, M2, L, E1, E2, Q1, Q2 and n are as defined herein, are useful as anti-angiogenesis agents, as agents for treatment of age related senile dementia, and as antiproliferative agents including, for example, as anticancer agents.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: November 15, 2011
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: E. Premkumar Reddy, M. V. Ramana Reddy
  • Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same
    Patent number: 8053435
    Abstract: The present invention discloses novel naphthalenyloxypropenyl derivatives useful for inhibiting the enzyme activity of histone deacetylase, leading effective suppression of cancer cell proliferation.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: November 8, 2011
    Assignees: Korea Research Institute of Chemical Technology, Crystalgenomics, Inc.
    Inventors: Cheol Hae Lee, Hee Jung Jung, Jae Hak Kim, Won Jang Jeong, Joong Myung Cho, Seong Gu Ro, Young Lan Hyun, Cheol Soon Lee, Dongkyu Shin
  • Benzophenone derivatives useful for inhibiting formation of microtubule
    Patent number: 8053439
    Abstract: Disclosed herein are novel benzophenone derivatives represented by formula I, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, a pharmacological composition containing the same, and a use of the composition as therapeutic drugs. The benzophenone derivatives have an inhibition activity of microtubule formation and can be used to treat a normal proliferative state of a malignant tumor by killing the actively proliferating cells.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: November 8, 2011
    Assignee: Chong Kun Dang Pharmaceutical Corp.
    Inventors: Nam-Song Choi, Young-Mi Kim, Young-Hoon Kim, Jae-Kwang Lee, In-Taek Lim, Ho-Jin Choi, Hyun-Mo Yang, Seung-Kee Moon, Soo-Jin Kim, Hyun-Jung Yu, Jae-Su Shin, Young-Min Kwon, Sung-Sook Lee, Soon-Kil Ahn, Sun-Ju Kong
  • Triazole compounds that modulate Hsp90 activity
    Patent number: 8053456
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: November 8, 2011
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Lijun Sun, Weiwen Ying, Junghyun Chae, Teresa Przewloka, Shijie Zhang, Dinesh U. Chimmanamada, Kevin Foley, Zhenjian Du, Hao Li, David James, Howard P. Ng, Zachary Demko, Dan Zhou, Shuzhen Qin
  • Antagonists of lysophosphatidic acid receptors
    Patent number: 8048902
    Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: November 1, 2011
    Assignee: Amira Pharmaceuticals, Inc.
    Inventors: John Howard Hutchinson, Thomas Jon Seiders, Bowei Wang, Jeannie M. Arruda, Jeffrey Roger Roppe, Timothy Parr
  • Macrocyclic inhibitors of hepatitis C virus replication
    Patent number: 8048862
    Abstract: The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: November 1, 2011
    Assignee: InterMune, Inc.
    Inventors: Scott D. Seiwert, Leonid Beigelman, Brad Buckman, Antitsa Dimitrova Stoycheva, Steven B. Porter, Williamson Ziegler Bradford, Vladimir Serebryany
  • Process for the preparation of olmesartan medoxomil
    Patent number: 8048904
    Abstract: The present invention provides a process for the preparation of Olmesartan medoxomil by condensing the ethyl 4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylate with 4-[2-(trityl tetrazol-5-yl)phenyl]benzyl bromide to obtain ethyl 4-(1-hydroxy-1-methyl ethyl)-2-propyl-1-{4-[2-(trityl tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate and then hydrolyzing ethyl 4-(1-hydroxy-1-methyl ethyl)-2-propyl-1-{4-[2-(trityl tetrazol-5-yl)phenyl]phenyl}methyl imidazole-5-carboxylate to obtain trityl Olmesartan dihydrate followed by reacting trityl Olmesartan dihydrate with 4-chloromethyl-5-methyl-2-oxo-1,3-dioxolene to obtain trityl Olmesartan medoxomil and then deprotecting trityl Olmesartan medoxomil to obtain Olmesartan medoxomil.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: November 1, 2011
    Assignee: Matrix Laboratories Ltd.
    Inventors: Gorantla Seeta Ramanjaneyulu, Bandari Mohan, Purna Chandra Ray, Madhuresh Kumar Sethi, Vijendra Singh Rawat, Yerramalla Raja Krishna, Vemula Lakshminarayana, Mamidi Srinivas
  • Compounds as calcium channel blockers
    Patent number: 8044069
    Abstract: The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar1, Ar2, L1, L2, n, R1, R4, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: October 25, 2011
    Assignees: Abbott Laboratories, Abbott GmbH & Co. KG
    Inventors: Pramila A. Bhatia, George A. Doherty, Irene Drizin, Helmut Mack, Richard J. Perner, Andrew O. Stewart, Qingwei Zhang
  • 1-acetic acid-indole derivatives with PGD2 antagonist activity
    Patent number: 8044088
    Abstract: Compounds of general formula (I) wherein R1 is halo or cyano; R2 is C1-C4 alkyl; and R3 is phenyl substituted with one or more substituents chosen from C1-C6 alkyl, halo or —SO2(C1-C6 alkyl); or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof; are useful in the treatment of diseases and conditions mediated by the action of PGD2 at the CRTH2 receptor.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: October 25, 2011
    Assignee: Oxagen Limited
    Inventors: Richard Edward Armer, Edward Andrew Boyd, Judith Helen Boyd, legal representative, Philip Andrew Hay
  • Amino-alkyl amide derivatives as CCR3 receptor ligands
    Patent number: 8044078
    Abstract: The invention relates to a compound of the general formula (I), as defined herein which is useful for the treatment of a pathology in a patient wherein a CCR3 receptor plays a role in the development of the pathology, and pharmaceutical preparations containing such compound. The invention is also directed to a process for preparing the compound of the general formula (I), and intermediate useful in the preparation.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: October 25, 2011
    Assignee: Sanofi-Aventis
    Inventors: Agnes Pappne Behr, Zoltan Kapui, Peter Aranyi, Sandor Batori, Veronika Bartane Bodor, Lajos T. Nagy, Mihalyne Santa, legal representative, Marton Varga, Endre Mikus, Katalin Urban-Szabo, Judit Vargane Szeredi, Tibor Szabo, Edit Susan, Marianna Kovacs